Trial Profile
Retrospective Observational Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Patients With BMI>25 kg/m^2, in Real World Clinical Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 25 Jul 2019 Status changed from recruiting to completed.
- 20 Jun 2019 Planned End Date changed from 30 May 2019 to 10 Jul 2019.
- 20 Jun 2019 Planned primary completion date changed from 30 May 2019 to 28 Jun 2019.